Israel’s BioLineRx has announced encouraging initial results from its Phase 2a trials of its BL-8040 treatment on patients with metastatic pancreatic cancer. After only five days of treatment the treatment substantially increased the numbers of T-cells fighting the tumors. https://www.prnewswire.com/news-releases/biolinerx-announces-partial-monotherapy-results-from-phase-2a-combat-study-in-pancreatic-cancer-300583808.html

In Davos, Israeli PM Netanyahu met with William McDermott, the CEO of SAP who agreed to partner with Israel on a new five-year NIS 1 billion digital healthcare project. The project aims to develop personalized and preventative medicine – regarded … Continue reading →

Israel-based startup Montfort Brain Monitor won Israel’s Henry Ford Health System’s artificial intelligence challenge. Montfort’s “master app” uses a smartphone’s sensors to track a patient’s motor, cognitive, and affective activity. It can be tailored for the specific neurological disorder. http://www.calcalistech.com/ctech/articles/0,7340,L-3730184,00.html

Israel’s VBL Therapeutics has opened its new gene therapy production facility to manufacture VBL’s lead cancer therapy ofranergene obadenovec (VB-111), when finally approved. The Modiin gene therapy plant is one of the largest in the world, and the first in … Continue reading →

This video shows that Israeli doctors are saving lives of cancer patients by testing different treatments on samples of the tumors outside of the patient’s body. They can then determine the best cancer treatments to offer patients based on the … Continue reading →

Viz.ai has received the CE Mark for its Israeli-developed Direct-to-Intervention system, ContaCT, a novel approach to stroke care that automatically analyzes brain CT-scans and notifies a specialist that a suspected large vessel occlusion has been identified. https://interventionalnews.com/viz-ai-announces-ce-mark-first-artificial-intelligence-powered-direct-intervention-system/ https://www.youtube.com/embed/_721LqeON3U?rel=0

Israel’s NRGene has confirmed the identity of a genetic mutation that causes colon cancer in 60% of its hosts. NRGene was contacted by scientists at Stanford University and used its GenoMagic software to genetically screen the DNA of inherited colon … Continue reading →

Post Injury Epilepsy (PIE) occurs several months after a stroke in at least 10% of patients. Scientists at Ben Gurion University have been able to detect likely PIE sufferers using EEG (electroencephalographic) recordings of theta brain waves. Early treatment with … Continue reading →

When Israel’s BioLineRx bought UK’s Agalimmune, it also acquired its AGI-134 treatment for solid tumors. BioLineRX has just demonstrated successful results of AGI-134 in two pre-clinical melanoma studies. https://www.prnewswire.com/news-releases/biolinerx-reports-data-at-asco-sitc-conference-showing-complete-tumor-regression-by-agi-134-in-pre-clinical-studies-670669553.html